[
  {
    "ticker": "AFP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975667",
    "id": "02975667",
    "pages": 4,
    "price_sensitive": false,
    "date": "20250801",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdwygggfj5k9.pdf",
    "summary": "<ul>\n<li><strong>Revenue milestone</strong>: FY revenue exceeded $200M for the first time ($208M total sales).  </li>\n<li><strong>Core market strength</strong>: Australasia delivered $181M in sales, supporting $300M FY27 revenue target.  </li>\n<li><strong>North American expansion</strong>:  </li>\n<li>Launched Maxigesic IV/tablet (Combogesic) in the US and Canada (combined addressable market &gt;US$8B).  </li>\n<li>Restructured US distribution to optimize postoperative care sales.  </li>\n<li><strong>Pipeline progress</strong>:  </li>\n<li>8 patented products in R&amp;D, 24 off-patent injectables, and 5 advanced programs entering commercialization (e.g., Crystaderm, Micolette).  </li>\n<li><strong>Financials</strong>:  </li>\n<li>Net debt reduced to $14.5M (from $16.2M).  </li>\n<li>Dividend increased to 1.8 cents/share (from 1.6 cents).  </li>\n<li><strong>Share price concerns</strong>: Management believes the share price undervalues growth potential and pipeline.  </li>\n<li><strong>Challenges</strong>: FY25 saw temporary headwinds (client destocking, doctors\u2019 strike), but H2 recovery occurred.  </li>\n</ul>\n<p>No material capital markets actions (e.g., raising, trading halts) identified.</p>",
    "usage": {
      "prompt_tokens": 1984,
      "completion_tokens": 258,
      "total_tokens": 2242,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-31T22:17:22.156940"
  },
  {
    "ticker": "AFP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975668",
    "id": "02975668",
    "pages": 30,
    "price_sensitive": false,
    "date": "20250801",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdx0kbh3x5mq.pdf",
    "summary": "<h3>Summary of ASX Announcement: <strong>AFT Pharmaceuticals 2025 Annual Shareholders' Meeting Presentation</strong></h3>\n<h4><strong>Key Financial Highlights</strong></h4>\n<ul>\n<li><strong>FY25 Revenue</strong>: NZ$208.0M (+6% YoY), with 5-year CAGR of 14%.  </li>\n<li><strong>ANZ Sales</strong>: NZ$180.9M (87% of total).  </li>\n<li><strong>Operating Profit</strong>: NZ$17.6M (down from NZ$24.2M in FY24) due to lower license income and strategic investments.  </li>\n<li><strong>Dividend</strong>: 1.8cps (up from 1.6cps in FY24).  </li>\n<li><strong>Net Debt</strong>: NZ$14.5M (down from NZ$16.2M in FY24).  </li>\n<li><strong>FY27 Target</strong>: Revenue of NZ$300M.  </li>\n</ul>\n<h4><strong>Operational &amp; Strategic Updates</strong></h4>\n<ul>\n<li><strong>International Expansion</strong>:  </li>\n<li>Products sold in ~80 countries; active R&amp;D pipeline of 8 patented products.  </li>\n<li>Launches in UK/EU (Combogesic IV), North America, Asia, and Africa.  </li>\n<li><strong>R&amp;D Progress</strong>:  </li>\n<li>24+ injectable products and 5 commercialized R&amp;D programs; key focus on Maxigesic variants (oral/IV) and dermatology (Crystaderm).  </li>\n<li><strong>Market-Specific Performance</strong>:  </li>\n<li><strong>Australia</strong>: +17% growth (eyecare/pain relief).  </li>\n<li><strong>Asia</strong>: Disrupted by Korean doctors\u2019 strike.  </li>\n</ul>\n<h4><strong>Outlook</strong></h4>\n<ul>\n<li>FY26 operating profit guidance: NZ$20M\u2013NZ$24M.  </li>\n<li>Focus on geographic and product diversification to drive growth.  </li>\n</ul>\n<p><strong>No capital raising, trading halt, or material M&amp;A disclosed.</strong></p>",
    "usage": {
      "prompt_tokens": 5861,
      "completion_tokens": 371,
      "total_tokens": 6232,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-31T22:17:13.437710"
  }
]